Introduction: Intranasal low-level laser therapy (LLLT) has already proven its immunosuppressive effects on allergic rhinitis (AR) in experimental studies; however, there is a dearth of clinical evidence supporting its effects in treating AR. The aim of this study was to assess the safety and effectiveness of intranasal LLLT in the treatment of AR compared with acupuncture.
Methods: A total of 80 patients with AR participated and were randomly assigned to the intranasal LLLT or acupuncture treatment (AT) group. They were given each treatment for 20 min 3 times a week for 4 weeks.
Results: Both groups improved the total nasal symptom score (TNSS), rhinoconjunctivitis quality of life questionnaire (RQLQ) score, and nasal endoscopy index in patients with AR after 4 weeks of treatment, and these effects extended 4 weeks after the end of treatment. Intranasal LLLT was noninferior to AT in regard to the TNSS. The estimated outcome difference between baseline and the 5th week was -0.38 points (upper 97.5% confidence limit 1.06 points), which was within the noninferiority margin of 2 points. The effect size of the TNSS at the 5th week was 0.19, which was close to Cohen's small effect size. There were no significant differences between two groups regarding the RQLQ, nasal endoscopy index, total serum immunoglobulin E level or absolute eosinophil count.
Conclusion: This study showed that intranasal LLLT is noninferior compared to AT in terms of the TNSS; thus, it may be used as an alternative or adjunctive treatment option for relieving symptoms of AR.
Trial Registration: This study was registered at the Korean National Clinical Trial Registry, Clinical Research Information Service (KCT0004079).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.explore.2022.02.006 | DOI Listing |
Photobiomodul Photomed Laser Surg
June 2024
University of Johannesburg, Doornfontein, South Africa.
Photobiomodulation therapy (PBMT) using devices to deliver red and/or near-infrared light to tissues has shown promising effects in clinical settings for respiratory diseases, including potential benefits in managing symptoms associated with COVID-19. To determine if at-home self-administered PBMT for patients with COVID-19 is safe and effective. This was a randomized controlled trial (RCT) carried out at home during the COVID-19 pandemic (September 2020 to August 2021).
View Article and Find Full Text PDFCells
June 2024
Department of Biomedical Engineering, Keimyung University, Daegu 42601, Republic of Korea.
Photobiomodulation (PBM) therapy on the brain employs red to near-infrared (NIR) light to treat various neurological and psychological disorders. The mechanism involves the activation of cytochrome c oxidase in the mitochondrial respiratory chain, thereby enhancing ATP synthesis. Additionally, light absorption by ion channels triggers the release of calcium ions, instigating the activation of transcription factors and subsequent gene expression.
View Article and Find Full Text PDFPhotobiomodul Photomed Laser Surg
June 2024
Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
This proof-of-concept study was to investigate the relationship between photobiomodulation (PBM) and neuromuscular control. The effects of concussion and repetitive head acceleration events (RHAEs) are associated with decreased motor control and balance. Simultaneous intranasal and transcranial PBM (itPBM) is emerging as a possible treatment for cognitive and psychological sequelae of brain injury with evidence of remote effects on other body systems.
View Article and Find Full Text PDFJ Biophotonics
February 2024
Multimodal Brain Image Analysis Laboratory, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Photobiomodulation, also called low-level light therapy, has been reported in animal studies to have an effect on brain activity and cognition. However, studies in humans regarding its effect on cognition and brain functional connectivity, and the required dose threshold for achieving the same have been very limited. We compared the effects of different doses of photobiomodulation (PBM) on cognition and resting state brain functional connectivity in 25 cognitively normal adults aged 55-70 years.
View Article and Find Full Text PDFJ Biophotonics
January 2024
School of Materials Science and Engineering, Hefei University of Technology, Hefei, China.
Photobiomodulation (PBM) therapy is an innovative treatment for neurological and psychological conditions. Complex IV of the mitochondrial respiratory chain can be stimulated by red light, which increases ATP synthesis. In addition, the ion channels' light absorption causes the release of Ca which activates transcription factors and changes gene expression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!